Jonathan J. Darrow
Harvard University
H-index: 27
North America-United States
Top articles of Jonathan J. Darrow
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Physicians’ Perspectives On FDA Regulation Of Drugs And Medical Devices: A National Survey: Study examines physicians’ perspectives, gathered from a national survey, on FDA … | Health Affairs | Sanket S Dhruva Aaron S Kesselheim Steven Woloshin Robin Z Ji Zhigang Lu | 2024/1/1 |
Leah Z. Rand, Daniel P. Carpenter, Aaron S. Kesselheim, Anushka Bhaskar, Jonathan J. Darrow, and William B. Feldman Reply | Hastings Center Report | Leah Z Rand Daniel P Carpenter Aaron S Kesselheim Anushka Bhaskar Jonathan J Darrow | 2024/3 |
CRISPR-phage antibacterials to address the antibiotic resistance crisis: scientific, economic, and regulatory considerations | Danielle M Pacia Beatrice L Brown Timo Minssen Jonathan J Darrow | 2024/1 | |
Securing the Trustworthiness of the FDA to Build Public Trust in Vaccines | Hastings Center Report | Leah Z Rand Daniel P Carpenter Aaron S Kesselheim Anushka Bhaskar Jonathan J Darrow | 2023/9 |
An Empirical Review of Key Glucose Monitoring Devices: Product Iterations and Patent Protection | Jonathan J Darrow Victor Van de Wiele David Beran Aaron S Kesselheim | 2023 | |
Physician Perspectives on the Food and Drug Administration's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease | Clinical Pharmacology & Therapeutics | Sanket S Dhruva Aaron S Kesselheim Steven Woloshin Robin Z Ji Zhigang Lu | 2023/9 |
Frequency of Approval and Marketing of Biosimilars With a Skinny Label and Associated Medicare Savings | JAMA Internal Medicine | Alexander C Egilman Victor L Van de Wiele Benjamin N Rome Jonathan J Darrow S Sean Tu | 2023/1/1 |
Prioritizing Early Disease Intervention | Therapeutic Innovation & Regulatory Science | H Hugo Caicedo Jonathan J Darrow Julio C Caicedo Alex Pentland | 2023/11 |
Two views of cancer medicines: Imagery versus evidence | Health Marketing Quarterly | Jonathan J Darrow | 2023/4/3 |
Trust and Regulation: Assuring Scientific Independence in the FDA's Emergency Use Authorization Process | Journal of Health Politics, Policy and Law | Neeraj G Patel Aaron S Kesselheim Jonathan J Darrow | 2023/10/1 |
Variation in endpoints in FDA medication approvals: a review of acute and preventive migraine medications | Leigh K Sharpless Aaron S Kesselheim Serena L Orr Jonathan Darrow | 2023/9/5 | |
Insulin products and patents in the USA in 2004, 2014, and 2020: a cross-sectional study | The Lancet Diabetes & Endocrinology | Victor L Van de Wiele Aaron S Kesselheim David Beran Jonathan J Darrow | 2023/2/1 |
Pharmaceutical Innovation in Latin America and the Caribbean | Journal of Law, Medicine & Ethics | Verónica Vargas Jonathan Darrow | 2023/9 |
Evidence for Community Face Masking to Limit the Spread of SARS-CoV-2: A Critical Review | Health Matrix | Ian T Liu Vinay Prasad Jonathan J Darrow | 2023 |
Government Patent Use to Promote Public Health in the United States: Overcoming Nonpatent Exclusivities | Rebecca E Wolitz Aaron S Kesselheim Jonathan J Darrow | 2022/8 | |
New drug postmarketing requirements and commitments in the US: a systematic review of the evidence | Osman Moneer Beatrice L Brown Jerry Avorn Jonathan J Darrow Mayookha Mitra-Majumdar | 2022/4 | |
Recent Orange and Purple Book legislation suggests a need to bridge drug and biologic patent regimes | Nature Biotechnology | Bryan S Walsh Jonathan J Darrow Aaron S Kesselheim | 2022/2 |
Communication of drug efficacy information via a popular online platform | The Journal of the American Board of Family Medicine | Jonathan J Darrow Elizaveta Borisova | 2022/7/1 |
Trends in the quality of evidence supporting FDA drug approvals: results from a literature review | Beatrice L Brown Mayookha Mitra-Majumdar Krysten Joyce Murray Ross Catherine Pham | 2022/12/1 | |
An orange book landscape: drugs, patents, and generic competition | Food & Drug LJ | Jonathan J Darrow Daniel TC Mai | 2022 |
Co-Authors
